Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624286 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
NCT00624286 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 416 participants.
The verdict
NCT00624286, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
Study Summary
This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Placebo to indacaterol
- DRUG Indacaterol 150 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624286
The ClinicalTrials.gov registry entry for NCT00624286 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo to indacaterol is the first listed.
NCT00624286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00624286 about?
NCT00624286 is a clinical study titled "Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)". This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00624286?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2008-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00624286?
The interventions under investigation include: Placebo to indacaterol (DRUG), Indacaterol 150 μg (DRUG).
Who is sponsoring clinical trial NCT00624286?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.